Image credit: Ramon Lomeli

At Heated Meeting, Los Angeles Cannabis Regulators Express Frustration at Social Equity Rollout

“I didn’t think that it would take us this long to get to this point and I am disappointed with where we are at,” said Cat Packer of the Department of Cannabis Regulation.

California
CBD

In a First, a Cannabis-Derived Pharma Product Is Descheduled in the US

The DEA has taken Epidiolex, a CBD-based formula for rare forms of epilepsy, completely off its list of controlled substances. Why? The 2018 Farm Bill.

Lobbying

The Cannabis Industry Spent More On Lobbying Than Ever Before in 2019. What’s Next is Unclear.

Companies and organizations spent nearly $11 million on federal lobbying alone, vastly outpacing previous years. But given the coronavirus, 2020 is a mystery.

Newsletter

Canada: medical cannabis is essential • Canopy’s board transformation • Australia’s cannabis access review • & more…

An excerpt from recent editions of the Cannabis Wire Daily newsletter.